AustralieFrV1, PascalFrancis, Checkpoint, bibRecord, 005D87

Activity of Exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors : A Phase II Trial

Identifieur interne : 005D87 ( PascalFrancis/Checkpoint ); précédent : 005D86; suivant : 005D88

Activity of Exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors : A Phase II Trial

Auteurs : P. E. L Nning [Norvège, Italie, Australie, France, États-Unis, Argentine, Pays-Bas] ; E. Bajetta ; R. Murray ; M. Tubiana-Hulin ; P. D. Eisenberg ; E. Mickiewicz ; L. Celio ; P. Pitt ; M. Mita ; N. K. Aaronson ; C. Fowst ; A. Arkhipov ; E. Di Salle ; A. Polli ; G. Massimini

Source :

Journal of clinical oncology [ 0732-183X ] ; 2000.

RBID : Pascal:00-0297144

Descripteurs français

Pascal (Inist)
- Tumeur maligne, Glande mammaire, Femelle, Homme, Métastase, Essai clinique phase II, Exémestane, Toxicité, Anticancéreux, Postménopause, Chimiothérapie, Résistance traitement, Androstane dérivé, Hormonothérapie.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Androstane derivatives, Antineoplastic agent, Chemotherapy, Exemestane, Female, Human, Malignant tumor, Mammary gland, Metastasis, Negative therapeutic reaction, Phase II trial, Postmenopause, Toxicity.

Abstract

Purpose: To evaluate the antitumor activity and toxicity of a new steroidal aromatase inactivator, exemestane, in postmenopausal women with metastatic breast cancer who had progressive disease (PD) after treatment with a nonsteroidal aromatase inhibitor. Patients and Methods: In this phase II trial, eligible patients were treated with exemestane 25 mg daily (n = 241) followed, at the time PD was determined, by exemestane 100 mg daily (n = 58). Results: On the basis of the intent-to-treat analysis by independent review, exemestane 25 mg produced objective responses in 6.6% of patients (95% confidence interval [Cl], 3.8% to 10.6%) and overall success (complete response + partial response + no change for 24 weeks or longer) in 24.3% (95% Cl, 19.0% to 30.2%). The median durations of objective response and overall success were 58.4 weeks (95% Cl, 49.7 to 71.1 weeks) and 37.0 weeks (95% Cl, 35.0 to 39.4 weeks), respectively. increasing the dose of exemestane to 100 mg upon the development of PD produced one partial response (1.7%; 95% Cl, 0.0% to 9.2%). Both dosages were well tolerated and were discontinued because of adverse events in only 1.7% of patients. Conclusion: Exemestane 25 mg once daily seems to be an attractive alternative to chemotherapy for the treatment of patients with metastatic breast cancer after multiple hormonal therapies have failed.

Affiliations:

Argentine, Australie, France, Italie, Norvège, Pays-Bas, États-Unis
Hollande-Septentrionale, Lombardie
Amsterdam, Milan

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 005F17
to stream PascalFrancis, to step Curation: 000253

Links to Exploration step

Pascal:00-0297144

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Activity of Exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors : A Phase II Trial</title>
<author><name sortKey="L Nning, P E" sort="L Nning, P E" uniqKey="L Nning P" first="P. E." last="L Nning">P. E. L Nning</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Oncology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Bergen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Istituto Nazionale Tumori and Pharmacia & Upjohn</s1>
<s2>Milan</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Peter MacCallum Cancer Institute</s1>
<s2>East Melbourne, Victoria</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Peter MacCallum Cancer Institute</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Centre Rene Huguenin</s1>
<s2>St Cloud</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<wicri:noRegion>St Cloud</wicri:noRegion>
<wicri:noRegion>Centre Rene Huguenin</wicri:noRegion>
<wicri:noRegion>Centre Rene Huguenin</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Marin Oncology Associates Inc</s1>
<s2>Greenbrae, CA</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Marin Oncology Associates Inc</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Instituto A.H. Roffo</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
</inist:fA14>
<country>Argentine</country>
<wicri:noRegion>Instituto A.H. Roffo</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Netherlands Cancer Institute</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Pharmacia & Upjohn</s1>
<s2>Kalamazoo, MI</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pharmacia & Upjohn</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bajetta, E" sort="Bajetta, E" uniqKey="Bajetta E" first="E." last="Bajetta">E. Bajetta</name>
</author>
<author><name sortKey="Murray, R" sort="Murray, R" uniqKey="Murray R" first="R." last="Murray">R. Murray</name>
</author>
<author><name sortKey="Tubiana Hulin, M" sort="Tubiana Hulin, M" uniqKey="Tubiana Hulin M" first="M." last="Tubiana-Hulin">M. Tubiana-Hulin</name>
</author>
<author><name sortKey="Eisenberg, P D" sort="Eisenberg, P D" uniqKey="Eisenberg P" first="P. D." last="Eisenberg">P. D. Eisenberg</name>
</author>
<author><name sortKey="Mickiewicz, E" sort="Mickiewicz, E" uniqKey="Mickiewicz E" first="E." last="Mickiewicz">E. Mickiewicz</name>
</author>
<author><name sortKey="Celio, L" sort="Celio, L" uniqKey="Celio L" first="L." last="Celio">L. Celio</name>
</author>
<author><name sortKey="Pitt, P" sort="Pitt, P" uniqKey="Pitt P" first="P." last="Pitt">P. Pitt</name>
</author>
<author><name sortKey="Mita, M" sort="Mita, M" uniqKey="Mita M" first="M." last="Mita">M. Mita</name>
</author>
<author><name sortKey="Aaronson, N K" sort="Aaronson, N K" uniqKey="Aaronson N" first="N. K." last="Aaronson">N. K. Aaronson</name>
</author>
<author><name sortKey="Fowst, C" sort="Fowst, C" uniqKey="Fowst C" first="C." last="Fowst">C. Fowst</name>
</author>
<author><name sortKey="Arkhipov, A" sort="Arkhipov, A" uniqKey="Arkhipov A" first="A." last="Arkhipov">A. Arkhipov</name>
</author>
<author><name sortKey="Di Salle, E" sort="Di Salle, E" uniqKey="Di Salle E" first="E." last="Di Salle">E. Di Salle</name>
</author>
<author><name sortKey="Polli, A" sort="Polli, A" uniqKey="Polli A" first="A." last="Polli">A. Polli</name>
</author>
<author><name sortKey="Massimini, G" sort="Massimini, G" uniqKey="Massimini G" first="G." last="Massimini">G. Massimini</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0297144</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0297144 INIST</idno>
<idno type="RBID">Pascal:00-0297144</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">005F17</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000253</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">005D87</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">005D87</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Activity of Exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors : A Phase II Trial</title>
<author><name sortKey="L Nning, P E" sort="L Nning, P E" uniqKey="L Nning P" first="P. E." last="L Nning">P. E. L Nning</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Oncology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
</inist:fA14>
<country>Norvège</country>
<wicri:noRegion>Bergen</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Istituto Nazionale Tumori and Pharmacia & Upjohn</s1>
<s2>Milan</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Peter MacCallum Cancer Institute</s1>
<s2>East Melbourne, Victoria</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Peter MacCallum Cancer Institute</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Centre Rene Huguenin</s1>
<s2>St Cloud</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<wicri:noRegion>St Cloud</wicri:noRegion>
<wicri:noRegion>Centre Rene Huguenin</wicri:noRegion>
<wicri:noRegion>Centre Rene Huguenin</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Marin Oncology Associates Inc</s1>
<s2>Greenbrae, CA</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Marin Oncology Associates Inc</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Instituto A.H. Roffo</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
</inist:fA14>
<country>Argentine</country>
<wicri:noRegion>Instituto A.H. Roffo</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Netherlands Cancer Institute</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Pharmacia & Upjohn</s1>
<s2>Kalamazoo, MI</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Pharmacia & Upjohn</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bajetta, E" sort="Bajetta, E" uniqKey="Bajetta E" first="E." last="Bajetta">E. Bajetta</name>
</author>
<author><name sortKey="Murray, R" sort="Murray, R" uniqKey="Murray R" first="R." last="Murray">R. Murray</name>
</author>
<author><name sortKey="Tubiana Hulin, M" sort="Tubiana Hulin, M" uniqKey="Tubiana Hulin M" first="M." last="Tubiana-Hulin">M. Tubiana-Hulin</name>
</author>
<author><name sortKey="Eisenberg, P D" sort="Eisenberg, P D" uniqKey="Eisenberg P" first="P. D." last="Eisenberg">P. D. Eisenberg</name>
</author>
<author><name sortKey="Mickiewicz, E" sort="Mickiewicz, E" uniqKey="Mickiewicz E" first="E." last="Mickiewicz">E. Mickiewicz</name>
</author>
<author><name sortKey="Celio, L" sort="Celio, L" uniqKey="Celio L" first="L." last="Celio">L. Celio</name>
</author>
<author><name sortKey="Pitt, P" sort="Pitt, P" uniqKey="Pitt P" first="P." last="Pitt">P. Pitt</name>
</author>
<author><name sortKey="Mita, M" sort="Mita, M" uniqKey="Mita M" first="M." last="Mita">M. Mita</name>
</author>
<author><name sortKey="Aaronson, N K" sort="Aaronson, N K" uniqKey="Aaronson N" first="N. K." last="Aaronson">N. K. Aaronson</name>
</author>
<author><name sortKey="Fowst, C" sort="Fowst, C" uniqKey="Fowst C" first="C." last="Fowst">C. Fowst</name>
</author>
<author><name sortKey="Arkhipov, A" sort="Arkhipov, A" uniqKey="Arkhipov A" first="A." last="Arkhipov">A. Arkhipov</name>
</author>
<author><name sortKey="Di Salle, E" sort="Di Salle, E" uniqKey="Di Salle E" first="E." last="Di Salle">E. Di Salle</name>
</author>
<author><name sortKey="Polli, A" sort="Polli, A" uniqKey="Polli A" first="A." last="Polli">A. Polli</name>
</author>
<author><name sortKey="Massimini, G" sort="Massimini, G" uniqKey="Massimini G" first="G." last="Massimini">G. Massimini</name>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Androstane derivatives</term>
<term>Antineoplastic agent</term>
<term>Chemotherapy</term>
<term>Exemestane</term>
<term>Female</term>
<term>Human</term>
<term>Malignant tumor</term>
<term>Mammary gland</term>
<term>Metastasis</term>
<term>Negative therapeutic reaction</term>
<term>Phase II trial</term>
<term>Postmenopause</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Tumeur maligne</term>
<term>Glande mammaire</term>
<term>Femelle</term>
<term>Homme</term>
<term>Métastase</term>
<term>Essai clinique phase II</term>
<term>Exémestane</term>
<term>Toxicité</term>
<term>Anticancéreux</term>
<term>Postménopause</term>
<term>Chimiothérapie</term>
<term>Résistance traitement</term>
<term>Androstane dérivé</term>
<term>Hormonothérapie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose: To evaluate the antitumor activity and toxicity of a new steroidal aromatase inactivator, exemestane, in postmenopausal women with metastatic breast cancer who had progressive disease (PD) after treatment with a nonsteroidal aromatase inhibitor. Patients and Methods: In this phase II trial, eligible patients were treated with exemestane 25 mg daily (n = 241) followed, at the time PD was determined, by exemestane 100 mg daily (n = 58). Results: On the basis of the intent-to-treat analysis by independent review, exemestane 25 mg produced objective responses in 6.6% of patients (95% confidence interval [Cl], 3.8% to 10.6%) and overall success (complete response + partial response + no change for 24 weeks or longer) in 24.3% (95% Cl, 19.0% to 30.2%). The median durations of objective response and overall success were 58.4 weeks (95% Cl, 49.7 to 71.1 weeks) and 37.0 weeks (95% Cl, 35.0 to 39.4 weeks), respectively. increasing the dose of exemestane to 100 mg upon the development of PD produced one partial response (1.7%; 95% Cl, 0.0% to 9.2%). Both dosages were well tolerated and were discontinued because of adverse events in only 1.7% of patients. Conclusion: Exemestane 25 mg once daily seems to be an attractive alternative to chemotherapy for the treatment of patients with metastatic breast cancer after multiple hormonal therapies have failed.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0732-183X</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. oncol.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Activity of Exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors : A Phase II Trial</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LØNNING (P. E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BAJETTA (E.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MURRAY (R.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TUBIANA-HULIN (M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>EISENBERG (P. D.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MICKIEWICZ (E.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CELIO (L.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>PITT (P.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>MITA (M.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>AARONSON (N. K.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>FOWST (C.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>ARKHIPOV (A.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>DI SALLE (E.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>POLLI (A.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>MASSIMINI (G.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Oncology, Haukeland University Hospital</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
</fA14>
<fA14 i1="02"><s1>Istituto Nazionale Tumori and Pharmacia & Upjohn</s1>
<s2>Milan</s2>
<s3>ITA</s3>
</fA14>
<fA14 i1="03"><s1>Peter MacCallum Cancer Institute</s1>
<s2>East Melbourne, Victoria</s2>
<s3>AUS</s3>
</fA14>
<fA14 i1="04"><s1>Centre Rene Huguenin</s1>
<s2>St Cloud</s2>
<s3>FRA</s3>
</fA14>
<fA14 i1="05"><s1>Marin Oncology Associates Inc</s1>
<s2>Greenbrae, CA</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="06"><s1>Instituto A.H. Roffo</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
</fA14>
<fA14 i1="07"><s1>Netherlands Cancer Institute</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
</fA14>
<fA14 i1="08"><s1>Pharmacia & Upjohn</s1>
<s2>Kalamazoo, MI</s2>
<s3>USA</s3>
</fA14>
<fA20><s1>2234-2244</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20094</s2>
<s5>354000082464240070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0297144</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical oncology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose: To evaluate the antitumor activity and toxicity of a new steroidal aromatase inactivator, exemestane, in postmenopausal women with metastatic breast cancer who had progressive disease (PD) after treatment with a nonsteroidal aromatase inhibitor. Patients and Methods: In this phase II trial, eligible patients were treated with exemestane 25 mg daily (n = 241) followed, at the time PD was determined, by exemestane 100 mg daily (n = 58). Results: On the basis of the intent-to-treat analysis by independent review, exemestane 25 mg produced objective responses in 6.6% of patients (95% confidence interval [Cl], 3.8% to 10.6%) and overall success (complete response + partial response + no change for 24 weeks or longer) in 24.3% (95% Cl, 19.0% to 30.2%). The median durations of objective response and overall success were 58.4 weeks (95% Cl, 49.7 to 71.1 weeks) and 37.0 weeks (95% Cl, 35.0 to 39.4 weeks), respectively. increasing the dose of exemestane to 100 mg upon the development of PD produced one partial response (1.7%; 95% Cl, 0.0% to 9.2%). Both dosages were well tolerated and were discontinued because of adverse events in only 1.7% of patients. Conclusion: Exemestane 25 mg once daily seems to be an attractive alternative to chemotherapy for the treatment of patients with metastatic breast cancer after multiple hormonal therapies have failed.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B20E02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Glande mammaire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Mammary gland</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Glándula mamaria</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Femelle</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Female</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hembra</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Homme</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Human</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hombre</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Métastase</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Metastasis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Metástasis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Essai clinique phase II</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Phase II trial</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ensayo clínico fase II</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Exémestane</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Exemestane</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Exemestano</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Postménopause</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Postmenopause</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Postmenopausia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Résistance traitement</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Negative therapeutic reaction</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Resistencia al tratamiento terapeútico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Androstane dérivé</s0>
<s2>FR</s2>
<s5>29</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Androstane derivatives</s0>
<s2>FR</s2>
<s5>29</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Androstano derivado</s0>
<s2>FR</s2>
<s5>29</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Hormonothérapie</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Glande mammaire pathologie</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fN21><s1>199</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Argentine</li>
<li>Australie</li>
<li>France</li>
<li>Italie</li>
<li>Norvège</li>
<li>Pays-Bas</li>
<li>États-Unis</li>
</country>
<region><li>Hollande-Septentrionale</li>
<li>Lombardie</li>
</region>
<settlement><li>Amsterdam</li>
<li>Milan</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Aaronson, N K" sort="Aaronson, N K" uniqKey="Aaronson N" first="N. K." last="Aaronson">N. K. Aaronson</name>
<name sortKey="Arkhipov, A" sort="Arkhipov, A" uniqKey="Arkhipov A" first="A." last="Arkhipov">A. Arkhipov</name>
<name sortKey="Bajetta, E" sort="Bajetta, E" uniqKey="Bajetta E" first="E." last="Bajetta">E. Bajetta</name>
<name sortKey="Celio, L" sort="Celio, L" uniqKey="Celio L" first="L." last="Celio">L. Celio</name>
<name sortKey="Di Salle, E" sort="Di Salle, E" uniqKey="Di Salle E" first="E." last="Di Salle">E. Di Salle</name>
<name sortKey="Eisenberg, P D" sort="Eisenberg, P D" uniqKey="Eisenberg P" first="P. D." last="Eisenberg">P. D. Eisenberg</name>
<name sortKey="Fowst, C" sort="Fowst, C" uniqKey="Fowst C" first="C." last="Fowst">C. Fowst</name>
<name sortKey="Massimini, G" sort="Massimini, G" uniqKey="Massimini G" first="G." last="Massimini">G. Massimini</name>
<name sortKey="Mickiewicz, E" sort="Mickiewicz, E" uniqKey="Mickiewicz E" first="E." last="Mickiewicz">E. Mickiewicz</name>
<name sortKey="Mita, M" sort="Mita, M" uniqKey="Mita M" first="M." last="Mita">M. Mita</name>
<name sortKey="Murray, R" sort="Murray, R" uniqKey="Murray R" first="R." last="Murray">R. Murray</name>
<name sortKey="Pitt, P" sort="Pitt, P" uniqKey="Pitt P" first="P." last="Pitt">P. Pitt</name>
<name sortKey="Polli, A" sort="Polli, A" uniqKey="Polli A" first="A." last="Polli">A. Polli</name>
<name sortKey="Tubiana Hulin, M" sort="Tubiana Hulin, M" uniqKey="Tubiana Hulin M" first="M." last="Tubiana-Hulin">M. Tubiana-Hulin</name>
</noCountry>
<country name="Norvège"><noRegion><name sortKey="L Nning, P E" sort="L Nning, P E" uniqKey="L Nning P" first="P. E." last="L Nning">P. E. L Nning</name>
</noRegion>
</country>
<country name="Italie"><region name="Lombardie"><name sortKey="L Nning, P E" sort="L Nning, P E" uniqKey="L Nning P" first="P. E." last="L Nning">P. E. L Nning</name>
</region>
</country>
<country name="Australie"><noRegion><name sortKey="L Nning, P E" sort="L Nning, P E" uniqKey="L Nning P" first="P. E." last="L Nning">P. E. L Nning</name>
</noRegion>
</country>
<country name="France"><noRegion><name sortKey="L Nning, P E" sort="L Nning, P E" uniqKey="L Nning P" first="P. E." last="L Nning">P. E. L Nning</name>
</noRegion>
</country>
<country name="États-Unis"><noRegion><name sortKey="L Nning, P E" sort="L Nning, P E" uniqKey="L Nning P" first="P. E." last="L Nning">P. E. L Nning</name>
</noRegion>
<name sortKey="L Nning, P E" sort="L Nning, P E" uniqKey="L Nning P" first="P. E." last="L Nning">P. E. L Nning</name>
</country>
<country name="Argentine"><noRegion><name sortKey="L Nning, P E" sort="L Nning, P E" uniqKey="L Nning P" first="P. E." last="L Nning">P. E. L Nning</name>
</noRegion>
</country>
<country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="L Nning, P E" sort="L Nning, P E" uniqKey="L Nning P" first="P. E." last="L Nning">P. E. L Nning</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D87 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 005D87 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:00-0297144
   |texte=   Activity of Exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors : A Phase II Trial
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Activity of Exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors : A Phase II Trial

Activity of Exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors : A Phase II Trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri